Andrew Newland is Chief Executive of ANGLE plc. He has an MA in Engineering Science from the University of Cambridge and is a qualified Chartered Accountant. He has 18 years of medical diagnostics experience and has specialised in the liquid biopsy space for the last nine years.
Andrew founded ANGLE in 1994. In 1999, Andrew led the team that founded the medical diagnostic company, Acolyte Biomedica. Acolyte was the first ever spin-out of the Defence Science and Technology Laboratory (Dstl) Porton Down, which specialised in rapid diagnosis of MRSA the ‘hospital super-bug’. Andrew chaired the company for several years and successfully led the company through three major rounds of venture capital investment. Andrew also founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nutrition research institute. Andrew chaired the Board of Provexis, a specialist nutraceutical company with a heart-health product, through to its successful flotation in 2005.
Vice President; CEO ANGLE Biosciences, Inc.
Paul Smith is the CEO of ANGLE Biosciences, Inc.. Prior to joining ANGLE, Paul most recently served as President and CEO of Axela Inc. a company specializing in the development of multiplex biomarker tools. He has more than 30 years of experience in the life science instrumentation field with a diverse background in sales, marketing and field operations.
Chief Financial Officer
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over 30 years and is an expert on the development and growth of new technology-based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy with a special work focus, then in management consulting within KPMG's High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
Business Development Director
Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership. Michael joined ANGLE in 2009 to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers.
Director of Manufacturing & Regulatory Affairs
Martin is the Head of Manufacturing and Regulatory at ANGLE plc, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and first specialised in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.
Clinical Studies Director
Craig Miller joined ANGLE in March of 2016 as the Clinical Studies Director, where he is responsible for driving the clinical development activities of ANGLE. He has over 20 years of experience in the RUO and IVD diagnostics industry, including clinical trial management, clinical data management, biostatistics, regulatory submissions, and manuscript writing and editing (Craig is a co-author on over 80 peer-reviewed publications in the field of oncology and diagnostics).
Vice President Commercial Operations
Nick Claxton is VP Commercial Operations for ANGLE plc, and is responsible for forging corporate relationships and developing global distribution networks to commercialise ANGLE’s products and services.
Nick joined Becton Dickinson where he held the position of Business Director responsible for sales, marketing, client and technical services for 10 years. From there he moved to Roche as head of marketing, following the acquisition of Boehringer Mannheim. In 2000 Nick joined LGC (formerly Laboratory of the Government Chemist) as Director of Forensics, responsible for the 7 geographical laboratory sites along with the sales and marketing for the group. The role required direct relationships with the UK Government Home Office and the 43 constabularies of the UK and Northern Ireland.
In 2007 Nick joined the UK Board of Olympus Scientific as Scientific Director with responsibilities for the Clinical Chemistry and Microscopy divisions. In 2010 Nick became Business Director for a start-up company called Epistem, where they launched the first hand held PCR device (Genedrive) developed for field based TB testing along with other infectious diseases.
In 2015 Nick joined another start up, Premaitha Health as Chief Commercial Officer. Premaitha were the first company to achieve a CE/IVD for non invasive pre natal testing using next generation sequencing platforms.
Nick is also a non-executive director of two companies, MEMP ( Middle East Medical Portal) which helps small British medical companies enter the Middle East and Inception Associates which mentors early start ups through business planning and raising investment.
Head of Clinical Laboratories
Madeline Repollet joined ANGLE in 2020 as the Head of Clinical Laboratories. Dr. Repollet holds a PhD in Health Care Administration, a MS in Quality Assurance & Regulatory Affairs and a BS in Biology. She is Board Certified as a Cytotechnologist by the American Society for Clinical Pathology.
Madeline started her career working as a Cytotechnologist and managing Pathology Laboratories in Puerto Rico and Minnesota. In 1999, she joined Immunicon, where she worked for R&D, Engineering and Clinical Development. Madeline is co-developer of the CellSearch® CTC definition, establishing the first CellSearch® training program and managing laboratory logistics for the clinical studies that obtained De Novo clearance for CellSearch®.
Madeline has more than 30 years of clinical lab experience, 21 of those in the liquid biopsy space. Madeline has years of global laboratory management experience, working with clinical laboratories in the US, The Netherlands, Belgium and Italy. During that time, Madeline established clinical laboratory quality management systems compliant with CLIA and ISO 15189 and obtained licenses from the States of Pennsylvania, California, New York, Florida, Rhode Island and Maryland.
Madeline is co-author in several circulating tumor cells publications and holds two patents in those technologies.